Profile
Joseph Beaulieu worked as an Associate Director at Morningstar, Inc. from 2009 to 2011.
Prior to that, he worked as an Analyst at ABN AMRO Securities (USA), Inc. in 1999.
Currently, he is the Treasurer & Controller at Epizyme, Inc. since 2018.
Mr. Beaulieu completed his undergraduate degree at The University of Chicago and his graduate degree at the University of Illinois.
He also completed an undergraduate degree at the Wallace E Carroll School of Management.
Former positions of Joseph Beaulieu
| Companies | Position | End |
|---|---|---|
| EPIZYME, INC. | Comptroller/Controller/Auditor | 31/01/2023 |
Morningstar, Inc. (Research)
 Morningstar, Inc. (Research) Investment ManagersFinance Morningstar, Inc. (Research) is the investment research arm of Morningstar, Inc. (NASDAQ: MORN), an American financial services firm headquartered in Chicago, Illinois. The firm was founded by Joseph Mansueto in 1984 and provides independent portfolio information offering star ratings and analysis of managed funds. They also provide economic commentary and asset allocation information based on qualitative research. | Director of Research - Equity | 30/08/2011 |
| ABN AMRO Securities (USA), Inc. | Analyst-Equity | 30/10/1999 |
Training of Joseph Beaulieu
| The University of Chicago | Undergraduate Degree |
| University of Illinois | Graduate Degree |
| Wallace E Carroll School of Management | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
| ABN AMRO Securities (USA), Inc. | Finance |
Morningstar, Inc. (Research)
Morningstar, Inc. (Research) Investment ManagersFinance Morningstar, Inc. (Research) is the investment research arm of Morningstar, Inc. (NASDAQ: MORN), an American financial services firm headquartered in Chicago, Illinois. The firm was founded by Joseph Mansueto in 1984 and provides independent portfolio information offering star ratings and analysis of managed funds. They also provide economic commentary and asset allocation information based on qualitative research. | Finance |
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
- Stock Market
- Insiders
- Joseph Beaulieu
